A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

• Status: Recruiting
• Trial end date: 2025-06-02
• Target enrollment: 0
• Participant gender: All

Summary

The main aims of this 2-part study are:

• Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise specified (DLBCL-NOS), high-grade B cell lymphoma with double or triple hit rearrangement (HGBL-DH/TH) and HGBL-NOS, and chronic lymphocytic leukemia (CLL).

• Phase II: To evaluate the overall response rate (ORR) in patients with MM, DLBCL-NOS, HGBL-DH/TH, HGBL-NOS or CLL treated with IDP-121 at the recommended Phase 2 Dose (RP2D).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: IDP Discovery Pharma S.L.

Criteria

Inclusion Criteria:

1. Age ≥18 years

2. Performance status (ECOG) < 2

3. Life expectancy ≥3 months

4. Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements.

5. Patient has given voluntary written informed consent before performance of any study- related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.

6. Patients diagnosed with chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma not otherwise specified (DLBCL-NOS), high-grade B cell lymphoma with double or triple hit rearrangement (HGBL-DH/TH), HGBL-NOS and multiple myeloma (MM) who are ineligible to receive the available treatments.

7. Adequate hematological or biochemical parameters as specified below

1. Hemoglobin > 8.0 g/dl (without transfusion support within 7 days)

2. Platelets count > 75 x109/L (without transfusional support within 7 days)

3. Absolute neutrophil count (ANC) > 0.75 x109/L (without G-CSF support within 7 days)

4. Aspartate transaminase (AST): <2.5 x the upper limit range (in patients with no liver metastases or <5 x ULN in patients with liver metastases)

5. Alanine transaminase (ALT): < 2.5 x the upper limit range (in patients with no liver metastases or <5 x ULN in patients with liver metastases)

6. Total bilirubin: < 2 x the upper limit range.

7. Calculated or measured creatinine clearance: > 50 mL/min (calculated from the Cockcroft-Gault formula).

8. Left ventricular ejection fraction > 50% or above the Institutional Lower Limit of Normal (LLN), whichever is lower .

Exclusion Criteria:

1. Persistent clinically significant non-hematological toxicity related to previous treatments. The presence of alopecia and NCI-CTC grade <2 symptomatic peripheral neuropathy is allowed.

2. Pregnant or lactating women; men and women of reproductive potential* (as defined in the Appendix 2) who are not using effective contraceptive methods (combined hormonal contraception associated with inhibition of ovulation; progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual abstinenence).

*A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy

3. History of any other neoplastic disease in the last five years (except basal cell carcinoma, skin epithelioma or carcinoma in situ of any site)

4. History of clinically significant hypotension.

5. History of clinically significant allergic or hyper-sensitivity reactions.

6. History or known clinically significant vascular disease or known high risk of vascular disease (as assessed by the treating physician) including (but not limited to):

• Thromboembolism

• Peripheralarterialdisease - Vasculitis

7. Other relevant diseases or adverse clinical conditions:

• Congestive heart failure or angina pectoris, myocardial infarction within 12 months before inclusion in the study.

• Uncontrolled arterial hypertension or cardiac arrhythmias (i.e., requiring a change in medication within the last 3 months or hospital admission within the past 6 months).

• Historyofsignificantneurologicalorpsychiatricdisorders

8. Clinically significant or active infection.

9. Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis)

10. The patient is known to be human immunodeficiency virus (HIV) positive, Hepatitis B surface antigen-positive, active hepatitis C infection or CMV positive.

11. Concomitant anti-tumor therapy within 14 days prior to Day 1 of Cycle 1.

12. Prior allogeneic transplantation in the last 3 months or currently active GVHD with immunossupresive treatment

13. Limitation of the patient's ability to comply with the treatment or follow-up protocol.

14. If a COVID-19 vaccine is administered it should be done >72 hours prior to study treatment initiation or after the completion of the dose-limiting toxicity (DLT) period (if patient is participating in the dose-escalation phase").